Terrie Curran - Mar 1, 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: President and Chief Executive, Director
Signature: /s/ Larry Miller, Attorney-in-Fact for Terrie Curran
Stock symbol: PHAT
Transactions as of: Mar 1, 2023
Transactions value $: -$12,265
Form type: 4
Date filed: 3/3/2023, 05:59 PM
Previous filing: Jan 20, 2023
Next filing: Mar 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Sale	-$12.3K	-1.44K	-0.81%	$8.54	175K	Mar 1, 2023	Direct	F1, F2
holding	PHAT	Common Stock						2.24K	Mar 1, 2023	by 401(k)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022.
F2	Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.53 to $8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022.

Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.53 to $8.7614. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.